Chen J, Liu F L
Second Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2024 Jul 25;27(7):666-671. doi: 10.3760/cma.j.cn441530-20240425-00153.
Neoadjuvant therapy, as an important part of comprehensive treatment for locally advanced gastric cancer, has been recommended by various guidelines. Partial locally advanced gastric cancer patients can achieve pathologic complete response (pCR) after neoadjuvant therapy, thus achieving relatively good prognosis. However, there is still controversy over whether complete remission in local pathology can translate into survival benefits, whether pCR is equivalent to cure, and whether subsequent adjuvant therapy is needed. Therefore, how to predict patients who can achieve pathologic complete response after neoadjuvant therapy and identify truly cured patients is the direction of future exploration.
新辅助治疗作为局部进展期胃癌综合治疗的重要组成部分，已被各种指南推荐。部分局部进展期胃癌患者在新辅助治疗后可实现病理完全缓解（pCR），从而获得相对较好的预后。然而，局部病理完全缓解是否能转化为生存获益、pCR是否等同于治愈以及后续是否需要辅助治疗仍存在争议。因此，如何预测新辅助治疗后能实现病理完全缓解的患者以及识别真正治愈的患者是未来探索的方向。
